Importantly, we found that miR-550a-3-5p treatment sensitized vemurafenib resistance through YAP inhibition with reduced AKT activity in vemurafenib-resistant colon cancer and melanoma cells. The gene discussed is AKT1; the disease is malignant colon neoplasm.